SCHEMBL4106286

SCHEMBL4106286

O=C(Nc1cccc(OC(F)F)c1)Nc1cccc(OC(F)F)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.65
MEN1 O00255 6/20 0.65
KMT2A Q03164 6/20 0.65
LMNA P02545 5/20 0.65
HTT P42858 5/20 0.65
NPSR1 Q6W5P4 4/20 0.65
SMN1; SMN2 Q16637 4/20 0.65
EPHX2 P34913 2/20 0.64
GRM4 Q14833 2/20 0.62
KCNJ5 P48544 1/20 0.58
KCNJ3 P48549 1/20 0.58
TP53 P04637 1/20 0.57
TSHR P16473 1/20 0.57
TAS2R14 Q9NYV8 1/20 0.56
RAB9A P51151 4/20 0.53
NPC1 O15118 3/20 0.53
ALDH1A1 P00352 2/20 0.53
MITF O75030 1/20 0.53
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118632 0.95 MAPT (0.64) MAPTMEN1KMT2ALMNAHTT
SCHEMBL4113827 0.94 MAPT (0.75) MAPTMEN1KMT2ALMNAHTT
SCHEMBL4113474 0.92 MEN1 (0.59) MAPTMEN1KMT2ALMNAHTT
SCHEMBL4112724 0.92 TP53 (0.70) MAPTMEN1KMT2ALMNAHTT
SCHEMBL4105961 0.92 SMN1; SMN2 (0.65) MAPTMEN1KMT2ALMNAHTT
SCHEMBL4110392 0.91 MAPT (0.64) MAPTMEN1KMT2ALMNAHTT
SCHEMBL4113233 0.91 KMT2A (0.65) MAPTMEN1KMT2ALMNAHTT
SCHEMBL4106986 0.91 MEN1 (0.68) MAPTMEN1KMT2ALMNAHTT
SCHEMBL4117939 0.89 CNR1 (0.64) MAPTMEN1KMT2ALMNAHTT
SCHEMBL4116278 0.89 MAPT (0.56) MAPTMEN1KMT2ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MAPT 1654/4885MEN1 3273/4885KMT2A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.